Clinical Trial Update: First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study assessing safety, tolerability, and blood levels of MP0250 in cancer patients (Phase 1/2) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• MP0250

Snippet

Sponsor: Molecular Partners AG | Conditions: Neoplasms | Phase 1, Phase 2 | Status: COMPLETED